Vol 49 No 02

PARP inhibitors and prostate cancer: What urologists need to know

February 10, 2021

In this interview, Emmanuel S. Antonarakis, MD, provides an overview of rucaparib (Rubraca) and olaparib (Lynparza), discusses the key trials that led to their approvals, and explains the urologist’s role in their use.

Urology coding Q&A: Is CPT code 99072 being paid?

February 01, 2021

"Unfortunately, we have found that most if not all insurers do not pay for this code and additionally often have policies against charging patients for extra supplies, and balance billing would be a violation of their contract," write Jonathan Rubenstein, MD, and Mark Painter.

Pattern of metastatic spread impacts whether enzalutamide plus ADT improves PFS in prostate cancer

January 28, 2021

"Here we show that there are clear benefits in delaying radiographic progression or death, [PSA] progression, and other outcomes in the largest groups of men with metastatic hormone-sensitive prostate cancer and lymph node and bone metastases,” says Andrew Armstrong, MD.